Roundup faces a historic, multi-decade payout over its weed killer as Bayer settles thousands of U.S. claims; Supreme Court rulings shape its legal fate.
The nationwide settlement has been approved, covering current and future Roundup users who have or later develop non-Hodgkin lymphoma. Payouts vary by use and diagnosis, with average ranges reported; attorneys’ fees are included. The decision comes as Bayer faces ongoing litigation and a Supreme Court ruling that limits state-court claims.